V.F.Snegirev Archives of Obstetrics and GynecologyV.F.Snegirev Archives of Obstetrics and Gynecology2313-87262687-1386Eco-Vector3541310.18821/2313-8726-2017-4-4-201-207Research ArticleHYPERPLASTIC PROCESSES OF ENDOMETRIUM IN WOMEN OF PERIMENOPAUSAL AGE: CLINICAL ASPECTS OF THE PROBLEMBaburinDmitry V.MD, PhD, assistant of the Department of Obstetrics and Gynecology of the I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federationdr.baburin@gmail.comUnanyanA. L-SidorovaI. S-KudrinaE. A-IshchenkoA. I-I.M. Sechenov First Moscow State Medical University151220174420120721072020Copyright © 2017, Eco-Vector2017The aim of the study is to identify the most significant clinical and anamnestic risk factors for the onset and progression of endometrial hyperplastic processes and the development of malignant transformation of endometrium in women of perimenopausal age, with taking into account their importance on the basis of statistical analysis. Methods. Based on Spearman’s correlation analysis and determination the degree of dependence of the development of endometrial cancer (from 0 to 1) on clinical-anamnestic and diagnostic risk factors (risk ratio (RR) in groups), there were obtained coefficients for a mathematical model allowing with the use of the binary logistic regression method predict the risk of the appearance of endometrial cancer. Results. The most clinically and statistically significant risk factors for the progression of the pathological process of the endometrium, having a high RR (greater than 1) and a confidence interval of 95% (p < 0.05), are (in the order of significance): recurrence of the endometrial hyperplastic process, obesity, the pronounced blood flow in Ultrasound with color Doppler mapping, polycystic ovary syndrome, abnormal ovarian formations, infertility (primary and secondary), type 2 diabetes mellitus, combined uterine pathology (myoma and/or adenomyosis), hereditary predisposition to cancer development, hypertension, age of 50 years and older. Conclusion. The tactics of the management and treatment of patients with hyperplastic endometrial processes should be based on the detection of the degree of the risk of the progression of pathological processes and the development of the malignant transformation of the endometrium. The study of the individual prognosis of endometrial cancer in patients with hyperplastic endometrial processes currently is becoming increasingly important due to the need to construct a rational treatment plan of the management and performing the follow-up dispensary observation on the basis of a scientifically justified forecast. Results obtained during our work allowed us identify statistically significant risk factors for the development of endometrial cancer. There were obtained coefficients for the creation a reliable mathematical model. With the use of the method of binary logistic regression, it is possible to calculate the risk of developing cancer and choose an effective management tactic for patients with hyperplastic endometrial processes at the perimenopausal age.hyperplastic process of endometriumendometrial hyperplasiaendometrial cancerrisk factorsperimenopauseгиперпластический процесс эндометриягиперплазия эндометриярак эндометрияфакторы рискаперименопауза[Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина; 1989.][Кулаков В.И., Манухин И.Б., Савельева Г.М., ред. Гинекология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009.][Стрижаков А.Н., Давыдов А.И. Доброкачественные заболевания матки. М.: ГЭОТАР-Медиа; 2011.][Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2016 г. М.: МНИОИ им. П.А. Герцена; 2017.][Савельева Г.М., Серов В.Н. Предрак эндометрия. М.: Медицина; 1980.][Horn L.C., Schnurbusch U., Hentschel B. et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int. J. Gynecol. Cancer. 2004; 14(2): 348-53. doi: 10.1111/j.1048-891x.2004.014220.x][Хмельницкая Н.М., Нейштадт Э.Л., Халимджанов З.К. Трудности и ошибки диагностики атипичной гиперплазии эндометрия. Архив патологии. 2006; 68(6): 39-42][Guido R.S., Kanbour-Shakir A., Rulin M.C., Christopherson W.A. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J. Reprod. Med. 1995; 40(8): 553-5.][American College of Obstetricians and Gynecologists. Diagnosis of abnormal uterine bleeding in reproductive aged women. Practice Bulletin no. 128. Obstet. Gynecol. 2012; 120(1): 197-206. doi: 10.1097/AOG.0b013e318262e320.][Farquhar C.M., Lethaby A., Sowter M., Verry J., Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am. J. Obstet. Gynecol. 1999; 181(3): 525-9.][Joensuu E.I., Abdel-Rahman W.M., Ollikainen M. et al. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res. 2008; 68(12): 4597-605. doi: 10.1158/0008-5472.CAN-07-6645.][Win A.K., Young J.P., Lindor N.M. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 2012; 30(9): 958-64. doi: 10.1200/JCO.2011.39.5590.][Auranen A., Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet. Gynecol. Scand. 2011; 90(5): 437-44. doi: 10.1111/j.1600-0412.2011.01091.x.][Olson J.E., Sellers T.A., Anderson K.E., Folsom A.R. Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer. 1999; 85(11): 2444-9.][Стрижаков А.Н., Давыдов А.И. Гинекология: курс лекций. М.: ГЭОТАР-Медиа; 2008][Ricci E., Moroni S., Parazini F. et al. Risk factors for endometrial hyperplasia: results from case control study. Int. J. Gynecol. Cancer. 2002; 12(3): 257-60.][Armstrong A.J., Hurd W.W., Elguero S., Barker N.M., Zanotti K.M. Diagnosis and management of endometrial hyperplasia. Review article. J. Minim. Invasive Gynecol. 2012; 19(5): 562-71. doi: 10.1016/j.jmig.2012.05.009.][Friberg E., Orsini N., Mantzoros C.S., Wolk A. Diabetes mellitus and risk of endometrial cancer: a metaanalysis. Diabetologia. 2007; 50(7): 1365-74. doi: 10.1007/s00125-007-0681-5.][Gallagher E.J., LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann. N.Y. Acad. Sci. 2011; 1243: 54-68. doi: 10.1111/j.1749-6632.2011.06285.x.][Balbi G., Napolitano A., Seguino E., Scaravilli G., Gioia F. et al. The role of hypertension, body mass index, and serum leptin levels in patients with endometrial hyperplasia during premenopausal period. Clin. Exp. Obstet. Gynecol. 2012; 39(3): 321-5.][Epplein M., Reed S.D., Voigt L.F., Newton K.M., Holt V.L., Weiss N.S. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am. J. Epidemiol. 2008; 168(6): 563-70. doi: 10.1093/aje/kwn168.][Wise M.R., Jordan V., Lagas A., Showell M., Wong N. et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am. J. Obstet. Gynecol. 2016; 214(6): 689. e1-17. doi: 10.1016/j.ajog.2016.01.175.][Серов В.Н. Метаболический синдром: гинекологические проблемы. Акушерство и гинекология. 2006; Приложение: 9-10][Epplein M., Reed S.D., Voigt L.F., Newton K.W., Holt V.L. et al. Endometrial hyperplasia risk in relation to characteristics and exposures that influence endogenous hormone levels. Am. J. Epidemiol. 2008; 168(2): 563-70.][MacDonald P.C., Edman C.D., Hemsell D.L., Porter J.C., Siiteri P.K. Effect of obesity on conversion of plasma and rostenedione to estrone in postmenopausal women with and without endometrial cancer. Am. J. Obstet. Gynecol. 1978; 130: 448-55.][Kaye S.A., Folsom A.R., Soler J.T., Prineas R.J., Potter J.D. Association of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int. J. Epidemiol. 1991; 20: 151-6.][Подзолкова Н.М., Кузнецова И.В., Соловьева Е.В. Заместительная гормональная терапия в климактерии. Учебное пособие. М.: МИА; 2005.][Озолиня Л.А., Патрушев Л.И., Болдина Е.Б. Современные представления о патогенезе гиперпластических процессов эндометрия и возможности их лечения. Лечение и профилактика. 2013; 2: 106-12.][Ryan A.J., Susil В., Jobling T.W. et al. Endometrial cancer. Cell Tissue Res. 2005; 322(1): 53-61. doi: 10.1007/s00441-005-1109-5.][Fu Y.S., Gambone J.C., Berek J.S. Pathophysiology and management of endometrial hyperplasia and carcinoma. West. J. Med. 1990; 153(1): 50-61.][Станоевич И.В., Сидорова И.С., Кудрина Е.А., Коган Е.А., Залетаев Д.В. Клинические, морфологические и молекулярные особенности гиперпластических заболеваний матки: практические выводы. В кн.: Материалы XII Всероссийского научного форума «Мать и дитя». М.; 2011: 424-5.][Капустина И.Н., Сидорова И.С., Саранцев А.Н. Цветовое допплеровское картирование в диагностике рака эндометрия. SonoAce International. 2001; 9: 61-6.][Stolyarova I.V., Minko B.A., Sirazitdinov B.R. Capabilities of three-dimensional ultrasonic angiography in specify diagnostics of endometrial carcinoma. In: 19 International congress on anti- cancer treatment. Paris, February 5-8, 2008: 255-6.][Arslan M., Erdem A., Erdem M. et al. Transvaginal color Doppler ultrasonography for prediction of pre-cancerous endometrial lesions. Int. J. Gynaecol. Obstet. 2003; 80(3): 299-306.][Gallos I.D., Alazzam M., Clark T.J., Faraj R., Rosenthal A.N., Smith P.P., Gupta J.K. Management of endometrial hyperplasia. Green-top Guideline No. 67. RCOG/BSGE Joint Guideline; 2016.][Haoula Z., Salman M., Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum. Reprod. 2012; 27(5): 1327-31. doi: 10.1093/humrep/des042.][Duncan T. Management of endometrial hyperplasia. A clinical guideline recommended for use. Gynaecology Guidelines Committee; 2013.][Ismet Gün, Öznur Öner, Serkan Bodur, Özkan Özdamar, Vedat Atay. Is adenomyosis associated with the risk of endometrial cancer? Med. Glas. (Zenica). 2012; 9(2): 268-72.][Ищенко А.И., Кудрина Е.А., Станоевич И.В. Доброкачественные пролиферативные заболевания матки: социальные аспекты проблемы. Врач. 2008; 8: 14-6.][Адамян Л.В., ред. Сочетанные доброкачественные заболевания матки. Клинические рекомендации. М.; 2015.]